| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Fasiglifam (formerly known as TAK-875; TAK875) is a novel, long-acting, selective and orally bioavailable GPR40 agonist with anti-diabetic activity. It activates GPR40 with EC50 of 14 nM in human GPR40 expressing CHO cell line, and is 400-fold more potent than oleic acid. Takeda terminated the development activities for fasiglifam (TAK-875) as a treatment modality for type 2 diabetes due to concerns about liver safety. TAK-875 has a favorable pharmacokinetic profile which enables long-acting drug efficacy. TAK-875 exhibited potent agonistic activity and high binding affinity to the human GPR40 receptor. In addition, TAK-875 showed excellent agonist potency and selectivity for GPR40 receptor over other members of the FFA receptor family (e.g. EC50>10 μM for others).
| ln Vitro |
In CHO-hGPR40, fasiglifam (TAK-875) (0.01-10 μM) increases intracellular IP synthesis in a concentration-dependent manner with an EC50 of 0.072 μM. In CHO cells, facilifam (TAK-875) (0.1–10 μM) dose-dependently increases intracellular IP production[1]. [Ca2+]i increases concentration-dependently with facoldifam (TAK-875) (3-30 μM). TAK-875 (0.001-10 μM) dose-dependently increases insulin production from INS-1 833/15 cells in the presence of 10 mM glucose[2].
|
||
|---|---|---|---|
| ln Vivo |
In ZDF rats, fasiglifam (TAK-875) (10 mg/kg, po) raises plasma insulin levels. Without changing fasting normoglycemia, facsiglifam (TAK-875) (30 mg/kg, po) reduces hyperglycemia while fasting. doses that increase glucose tolerance in diabetic rats by three to ten times are found to be at 30 mg/kg, which has no effect on fasting glucose levels in SD rats with normal glucose homeostasis. In SD rats with normal fasting glucose levels, Fasiglifam (TAK-875) does not significantly change insulin secretion [1].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Fasiglifam is a member of biphenyls.
Fasiglifam has been used in trials studying the treatment of Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Diabetes Mellitus, Type 2. |
| Molecular Formula |
C29H32O7S.1/2H2O
|
|
|---|---|---|
| Molecular Weight |
533.63
|
|
| Exact Mass |
524.186
|
|
| CAS # |
1000413-72-8
|
|
| Related CAS # |
(R)-Fasiglifam;1234474-57-7;Fasiglifam hemihydrate;1374598-80-7
|
|
| PubChem CID |
24857286
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
739.1±60.0 °C at 760 mmHg
|
|
| Flash Point |
400.8±32.9 °C
|
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
|
| Index of Refraction |
1.587
|
|
| LogP |
4.36
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
11
|
|
| Heavy Atom Count |
37
|
|
| Complexity |
828
|
|
| Defined Atom Stereocenter Count |
1
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: 0.5% CMC+0.25% Tween 80 : 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8740 mL | 9.3698 mL | 18.7396 mL | |
| 5 mM | 0.3748 mL | 1.8740 mL | 3.7479 mL | |
| 10 mM | 0.1874 mL | 0.9370 mL | 1.8740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
